X0202 SCHEDULE 13G 0002052389 XXXXXXXX LIVE Class A Ordinary Shares, no par value 10/08/2026 0001723980 China SXT Pharmaceuticals, Inc. G2161P157 178 Taidong Rd North Taizhou, Jiangsu F4 640695 Rule 13d-1(c) Orca Capital AG 2M 1112788.00 0.00 1112788.00 0.00 1112788.00 N 9.9 CO All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 10,357,498 Class A ordinary shares outstanding immediately after giving effect to the completion of the Issuer's registered offering as provided in the Issuer's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on October 9, 2026, and excludes 887,212 Class A ordinary shares issuable upon the exercise of pre-funded warrants and 2,000,000 Class A ordinary shares issuable upon the exercise of common warrants, subject to the 9.99% Blocker (defined below). Pursuant to the terms of the pre-funded warrants and the common warrants, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the Issuer's outstanding Class A ordinary shares (the "9.99% Blocker"). China SXT Pharmaceuticals, Inc. 178 Taidong Rd North, Taizhou, Jiangsu, China Orca Capital AG Sperlring 2 85276 Hettenshausen Deutschland Germany Y 1,112,788 9.9 % 1,112,788 0 1,112,788 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Orca Capital AG /s/ Thomas Konig 10/15/2026